Source comparison
Tesamorelin Visceral Fat Reduction Research Mechanism: Peptide Comparison
Tesamorelin GHRH receptor agonist. Stimulates pulsatile endogenous GH secretion High. Targets visceral adipocytes via elevated GH receptor density 15.2% median reduction (Lancet 2010 trial) 26–38 minutes (GH elevation lasts 3–4 hours) Gold standard for selecti
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH receptor agonist. Stimulates pulsatile endogenous GH secretion
- High. Targets visceral adipocytes via elevated GH receptor density
- 15.2% median reduction (Lancet 2010 trial)
- 26–38 minutes (GH elevation lasts 3–4 hours)
- Gold standard for selective VAT reduction without systemic weight loss. Preserves subcutaneous fat and lean mass
- CJC-1295 (DAC)
- GHRH analogue with extended half-life via drug affinity complex
- Moderate. Sustained GH elevation but less pulsatile
- No published Phase III VAT-specific data
- 6–8 days
- Longer half-life reduces injection frequency but sacrifices pulsatility. May cause receptor desensitization over time
- Ipamorelin
- Ghrelin mimetic (growth hormone secretagogue)
- Low. Broad GH secretion without VAT specificity
- No published VAT reduction trials
- 2 hours
- Primarily used for anabolic effects and appetite modulation. Not validated for targeted fat loss
- AOD-9604
- Modified C-terminal fragment of human GH
- Moderate. Lipolytic without full GH receptor activation
- Inconsistent results across trials. No FDA approval
- 30–60 minutes
- Originally developed for obesity treatment but failed to demonstrate reproducible fat loss in Phase II/III trials